Podcasts about Cancer research

Teresa Baglietto has lived through the kind of compounded harm that exposes how thin the safety net really is. In this episode she walks through a life shaped by medical neglect, personal violence, and the exhausting labor of self advocacy. She nearly died after a C section when hospital staff failed to confirm she had urinated before discharge, spending 15 days hospitalized and separated from her newborn while facing the possibility of permanent damage. In 2013 she discovered an aggressive breast cancer and waited weeks for test results and surgery while administrators stalled and passed responsibility. Care only moved forward after she threatened public exposure. Teresa also speaks openly about surviving rape in high school, losing her father to cancer at age 48 when she was 10, and growing up without reliable adults in the room. She explains why it took 7 years to write her book, why she launched a podcast, and how sales grit becomes a survival tool when patients must fight systems designed to delay them. The conversation stays specific, unsentimental, and grounded in consequence.RELATED LINKSTeresa Baglietto on LinkedInThe Ripple Effect by Teresa BagliettoIn Shock PodcastIn Shock Podcast on InstagramCanvas Rebel interview with Teresa BagliettoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the body already knows how to heal, and the missing piece is learning how to get out of its way? Bob Ross has spent a lifetime at the intersection of science, medicine, emergency response, and human potential. With a background in physics, medical research, and decades of hands-on experience helping people survive trauma, Bob has seen firsthand how unresolved emotional shock can quietly shape physical health, behavior, and identity. In this episode, Bob Ross and Chuck Thuss explore the deep connection between emotional trauma and the body's biological responses. From cancer research and PTSD to addiction, phobias, and chronic pain, Bob explains why healing often begins not with fighting symptoms, but with resolving what the nervous system is still holding onto. This conversation challenges conventional thinking and invites listeners to reconsider what true healing really looks like. Guest Bio Bob Ross is a physicist, medical researcher, bestselling author, and lifelong first responder with nearly four decades of service as an EMS professional and training officer with the Pasadena Fire Department. With advanced training in medical physics and cancer research, Bob contributed to major discoveries in oncology and later stepped away from traditional treatment models to focus on healing at the root level. Bob has worked with the U.S. Secret Service, served as a motion picture and television set medic, received both Presidential and Congressional awards for lifesaving service, and comes from a family lineage of inventors holding over 150 patents. Today, he helps individuals heal trauma, PTSD, phobias, addiction, and chronic conditions by addressing the nervous system and subconscious mind through science-backed, trauma-informed methods.   You'll hear About How emotional trauma creates real biological responses in the body Why unresolved shock can manifest as illness, pain, or addiction The link between trauma, the nervous system, and immune function Why healing symptoms without addressing root causes often fails Practical ways to begin emotional healing safely and effectively Chapters 00:00 Welcome and Episode Introduction 02:30 Bob's Early Life and Path Into Science and Medicine 06:00 Medical Physics, Cancer Research, and Walking Away 10:30 Emotional Trauma as a Biological Event 15:00 PTSD, Shock, and the Nervous System 19:30 Why the Body Creates Symptoms to Protect Us 24:00 Trauma, Addiction, and Survival Behaviors 28:30 The Role of Safety in Healing 32:30 Real-World Stories of Recovery and Resolution 38:00 Why Talk Therapy Alone Often Falls Short 42:00 Practical Tools for Healing Emotional Trauma 45:30 Where to Learn More and Access Resources 48:00 Chuck's Closing Reflections Chuck's Challenge This week, pay attention to your body's signals instead of fighting them. When discomfort, stress, or emotion shows up, pause and ask, "What might my body be trying to protect me from?" Approach yourself with curiosity rather than judgment. Healing often begins with listening. Connect with Bob Ross Website: https://www.thehiddensecrettohealing.com/ Link to Services: https://thehiddensecrettohealing.systeme.io/8707482d Connect with Chuck Check out the website: https://www.thecompassionateconnection.com/ Linked In: https://www.linkedin.com/in/chuck-thuss-a9aa044/ Follow on Instagram: @warriorsunmasked Join the Warriors Unmasked community by subscribing to the show. Together, we're breaking stigmas and shining a light on mental health, one story at a time.

Jay's YOUTUBE Channel HERE!! https://youtube.com/@schwedelson?si=xh3t_FkFtqCSMd1dA quick movie debate somehow turns into a really useful reality check on modern marketing, which feels exactly right for this series. Jay Schwedelson and Daniel Murray get honest about what is actually moving the needle right now, from YouTube frustrations to why one-off influencer buys usually fall flat. The best part is how practical it gets once they stop pretending every channel is a guaranteed win.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(02:10) Jay shares that 300 YouTube videos brought views, but barely any meaningful conversions.(03:03) Daniel says one-off influencer deals are usually a weak bet if you want real impact.(04:45) Bigger creator partnerships work better when they are built like a strategy, not a single post.(05:00) March Madness references can give boring content a timely lift in opens, clicks, and engagement.(06:15) Daniel makes the case for building an AI brain with customer data, reviews, and brand voice now.(07:45) Jay says testimonial-only subject lines are quietly driving strong backend conversions.ㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

AP correspondent Julie Walker reports from rockets to cancer research, here's how the number pi is embedded in our lives.

Networking advice is usually either painfully obvious or way too vague, but this one gets refreshingly specific. Jay Schwedelson gets blunt about what it actually takes to build the right relationships before you need them, and why most people are playing the networking game way too passively. It feels less like polished career advice and more like the push you need when resumes, promotions, or outreach are going nowhere.ㅤBest Moments:(01:09) LinkedIn is a long game, and 15 intentional minutes a day can change a lot.(02:10) Want higher-level people to notice you? Comment thoughtfully on their posts for weeks before you hit connect.(04:15) Start lower in the org chart so senior people see you already know their team.(05:38) Stop going to business events just to hang out and decide in advance who you need to meet.(07:44) Ask for introductions because one warm intro can shift your business or your career.(10:12) Jay takes his first pickleball lesson and immediately decides the sport has way too many rules.ㅤMASSIVE thank you to our Sponsor, CallRail!CallRail is the AI-powered lead intelligence platform that helps marketers prove exactly what's driving results. With CallRail, you can connect every call, text, chat, and form submission directly to the campaign that generated it so you finally know what's working and where to double down.Plus, with built-in AI conversation intelligence, CallRail analyzes your customer conversations, captures leads 24/7, and gives you deeper insights into what your prospects actually care about.If you're tired of guessing about your marketing ROI and want real data behind your campaigns, CallRail has you covered.Start a Free Trial Here: https://www.callrail.com/dothisㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Visit ZeroBounce.net to access free tools for email validation and warmup, or connect with Brian directly on LinkedIn.ㅤEveryone thinks they know why their emails hit the spam folder, but Brian Minick is here to prove most of us wrong. As the COO of ZeroBounce, he breaks down the real technical reasons behind deliverability without making it sound like a boring lecture. Jay Schwedelson presses him on the biggest myths in email marketing, including the truth about using the word "free" in your subject lines.ㅤBest Moments:(02:30) Why hitting 100% inbox placement is actually impossible(04:09) The truth about using trigger words like "free" in your subject lines(04:51) Why unsubscribes actually help your sender reputation(05:46) You should want your sales emails to land in the Promotions tab(07:30) How to safely migrate email platforms without ruining your deliverability(09:00) The real difference between shared and dedicated IP addressesㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Science likes to call itself a meritocracy. Angela Anderson and Brandi Mattson know better. Both served as editors at elite journals (Cell and Neuron), where a single decision could determine who gets tenure, funding, or obscurity. They watched brilliant data get filtered out because the authors did not know the unwritten rules controlled by 5 dominant publishing houses with profit margins higher than Google.In 2020, amid pandemic shutdowns and national reckoning over racial injustice, they co-founded a nonprofit to expose that hidden curriculum. Through the JEDI program, they provide 10 hours of free editorial consulting to scientists who lack access to elite networks. In 1 year alone, 25 awards helped researchers salvage canceled grants, secure NSF career funding, and rebuild careers derailed by rejection.This episode pulls back the curtain on the multibillion dollar publishing engine that profits from taxpayer funded science and reveals who gets heard, who gets sidelined, and how insiders are choosing to redistribute power.RELATED LINKSAngela AndersonBrandy MattsonLife Science EditorsLife Science Editors FoundationCellNeuronNational Science FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Leah& listeners share our Lent Loopholes, Lisa Rinna's new book does not disappoint and Mindy Dykes from Children's Cancer Research joins us for our She Speaks series See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Have you ever wondered whether an $11 fast-food burger is actually meant for human consumption? This week's quick update explores the bizarre viral moment at McDonald's and examines why luxury fashion brands are suddenly making smart glasses. Jay Schwedelson also breaks down a shockingly simple website pop-up trick that generates massive conversions but is ignored by almost everyone.ㅤBest Moments:(01:00) The rumor of Prada smart glasses after Mark Zuckerberg was spotted at Milan Fashion Week(01:41) How timed popups on pricing pages can generate a massive conversion rate(03:00) The sudden rush of major retail and travel brands running ads directly on ChatGPT(05:45) The viral disaster of the McDonald's CEO taking a tiny bite of a new massive burger(07:43) Presale details for Jay's upcoming book and how the proceeds support cancer researchㅤMASSIVE thank you to our Sponsor, CallRail!CallRail is the AI-powered lead intelligence platform that helps marketers prove exactly what's driving results. With CallRail, you can connect every call, text, chat, and form submission directly to the campaign that generated it so you finally know what's working and where to double down.Plus, with built-in AI conversation intelligence, CallRail analyzes your customer conversations, captures leads 24/7, and gives you deeper insights into what your prospects actually care about.If you're tired of guessing about your marketing ROI and want real data behind your campaigns, CallRail has you covered.Start a Free Trial Here: https://www.callrail.com/dothisㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Today's episode of Out of Patients welcomes Dr Pamela Buchanan, an emergency room physician with over 20 years inside American medicine who refuses to sugarcoat what the job demands and what it destroys. She worked straight through COVID as protocols changed by the day and deaths arrived faster than anyone could process. She logged 80 to 100 hour weeks. She isolated from her family to avoid bringing the virus home. Over time, survival began to feel negotiable.Dr Buchanan speaks openly about burnout as emotional flatline and about physician suicide as a predictable outcome that leadership prefers to ignore. She describes the ER as the catch all for a broken system and explains why chronic care collapses there by design. She shares the reality of trying to access mental health care while still practicing medicine, calling dozens of therapists, getting nowhere, and spending $10,000 to $15,000 out of pocket just to stay alive and functional.Listeners will hear how neurodivergence shaped her career in emergency medicine, how race and trust intersect inside hospital walls, and why doctors are leaving in waves. This conversation carries clarity, anger, humor, and hard earned truth from someone who stayed long enough to name the damage.RELATED LINKSDr Pamela BuchananStrong MedicineDr Pamela Buchanan on LinkedInDr Pamela Buchanan on InstagramEmotional Flatline articleKevinMD essay by Dr Pamela BuchananFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Jay Schwedelson and Daniel Murray for a quick "Bathroom Break" that starts with a cringey social dilemma involving a nose-picker and a handshake. They debate the rules of public coughing and why Daniel immediately flees restaurants upon hearing a sneeze. On the marketing side, they break down the 90-day repurposing rule and explain why your fear of being repetitive is completely unfounded.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(01:09) Jay recounts a horror story about a thumb up the nose right before a greeting(01:51) Daniel reveals the fake phone call move he uses to avoid gross handshakes(02:40) Why does hearing a sneeze at a restaurant make Daniel leave immediately(03:45) The 90-day window where old content becomes new again(05:32) How to reuse a winning hook without the algorithm punishing you(07:28) The realization that nobody remembers what you posted on Tuesday(11:00) A passionate rant about why hand sanitizer is not a substitute for soapㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Stop losing leads just because your landing page looks like work. Jay Schwedelson reveals the psychological triggers that make people click submit, including a simple image trick that bumps conversions by double digits. He also opens up about the "woo woo" morning habit that keeps him sane, even if it involves hiding in the bathroom.ㅤBest Moments:(02:45) How repeating your email's hero image on the landing page subconsciously builds trust(03:50) The exact percentage of leads you lose for every single extra field you require(04:29) Why splitting long forms into multiple steps can skyrocket your completion rate(05:25) The specific spot to place a testimonial that drives a 15% conversion lift(06:45) One navigation mistake that kills focus and why you need to delete it right now(08:50) Jay's 10-minute morning ritual that happens before he ever looks at a phone screenㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Resveratrol + Copper Research, Plus Grain-Free Strategies for Stalled Weight Loss: Leyla Muedin, a registered dietitian nutritionist, answers listener emails. She reviews a small India study (BJC Reports, published September 30, 2025) in which 10 glioblastoma patients awaiting surgery received resveratrol (5.6 mg) and copper (560 ng) four times daily for about 11.6 days, compared with 10 controls; the combination generated reactive oxygen species that deactivated cell-free chromatin particles in the tumor microenvironment and reduced cancer hallmarks. Asked whether this could be prophylactic against cancer, she says it is unknown and requires replication in larger studies, advising supplement use be discussed with a practitioner. She then addresses grain elimination for stalled weight loss: replace grains with more meat and non-starchy vegetables, think beyond typical breakfast foods by using leftovers, and use small portions of starchy vegetables (e.g., squash or potato) if starch helps sleep. She recommends investigating root causes of anxiety and poor sleep and suggests moderation for foods like oatmeal.

Russell Brunson joins Jay Schwedelson to reveal why traditional websites are dead and how a simple funnel can completely change your business trajectory. Russell breaks down exactly how he used AI to pull off his biggest launch ever and shares the "webinar a week" strategy that took ClickFunnels from zero to $10 million in revenue.ㅤRussell encourages everyone to start with his books—DotCom Secrets for funnel basics, Expert Secrets for messaging, and Traffic Secrets for getting eyeballs—or jump straight into the ClickFunnels community.ㅤBest Moments:(01:34) Why a confused mind always says no and how to fix it immediately(04:47) Using AI to analyze competitors and build a perfect marketing campaign(08:30) How to get $150k worth of consulting for free using simple AI tools(09:33) The specific weekly webinar strategy that took ClickFunnels to $10M(11:00) Real-time feedback loops that can double your sales during a live presentation(15:19) Why you should never stop telling your core stories even if you are bored of themㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Dr. Barbara Paldus is the Founder and CEO of CODEX Labs, the sponsor of this episode.She grew up around Nobel Prize winners, built biotech manufacturing equipment for vaccines and cancer therapeutics, and then sold her company after an 8 year old threatened suicide.Her son's severe eczema pushed her into an unregulated $100,000,000,000 skincare market where parents are told to trust labels that nobody verifies. She explains how corticosteroid ladders leave patients with years long withdrawal, why U.S. ingredient oversight lags Europe, and how chemotherapy destroys the same skin and gut barriers seen in inflammatory disease.The conversation tracks the real stakes behind “clean” marketing: a child's immune system, hospital infections like MRSA, and patients trying to survive treatment without new damage. She also details the research path from Irish medical manuscripts to microbiome science and why sick populations become the only reliable regulators when policy fails.RELATED LINKSBarbara PaldusCodex LabsSekhmet VenturesDr Peter LioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

Earlier this year, Congress pushed back on the Trump administration's attempts to slash funding for many science research programs, and restored that money to the budget. But despite the funds existing in the budget, they have not yet been released to some researchers.  Science journalist Alexandra Witze joins Host Ira Flatow to walk through the details of the government funding process, and her recent report in Nature about the funding slowdown.  Guest: Alexandra Witze is a correspondent for the journal Nature. She's based in Boulder, Colorado. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Get your FREE copy of "Your A-Z Guide to Staying Cancer Free" here: https://dramycancer.com/azcancerfree   You like doing your own research - but it turns out, you are doing it all wrong!   As a cancer survivor or thriver, I know you want to take control of your diagnosis.  You want to gain some power back.  Doing your own research can be very powerful.  But you need to make sure you are doing it right.    The problem - so many people fall for the same mistakes when it comes to doing cancer research.  Do not be the same.   So let me show you how it's done.   Join the Cancer Freedom Program Click HERE https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast   #cancerfighter #cancersurvivor #breastcancer #breastcancersurvivors #cancerrecovery  #cancernutrition #mastectomy #tamoxifen #anastrozole #letrozole #exemestane    ***PS - Whenever you're ready, here are the 2 best ways I can help you… 1) "Your A-Z Guide to Staying Cancer Free" **FREE** Click HERE https://dramycancer.com/azcancerfree   2) Join the Cancer Freedom Program Click HERE https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast   ***Let's Connect: Website: https://www.cancerfreedomprogram.com/?utm_source=podcast&utm_content=cancer_freedom_podcast Instagram: https://www.instagram.com/dramymorris/  

Drove to Kentucky to visit one of the most lethal anglers in that region right now, Luke Lamb. Enjoy as we take some deep dives, share stories, talk scoping techniques, JDM lures, and more. One things for sure, after this episode, its easy to understand why Lamb Chop is an absolute Hammer. Thank you to co-host and fellow Basstronaut, Ricky Harris, for letting us use his basement. Thank you Luke Lamb! Keep an eye on this dude.Support St. Jude Children's Cancer Research, every dollar helps support kids who need it more than we do! --> Click to DonateSneaky JDM Tackle & More --> Thorne Bros - the ultimate tackle destination! NEW Limited Edition Drops at Vocelka Fishing & Customs click the link to see all the latest!#tealsbassgalaxy #fishingpodcast #lambchop #ricky #bassfishing #kentucky #minnesota

Everyone wants their content to show up in AI recommendations, but most marketers are missing a simple formatting tweak that boosts visibility by 42%. Jay Schwedelson breaks down new data from Google that proves why adding a specific month to your titles is now critical for ranking. He also discusses why the head of Instagram is actually encouraging creators to leave mistakes in their videos and how "proof of life" is the new engagement hack.ㅤBest Moments:(00:45) New data from Google reveals exactly how to format dates to win in AI search(01:03) Why adding the specific month to your titles increases visibility by 42%(02:15) eBay buying Depop is a huge signal for where Gen Z commerce is actually happening(03:30) Adam Mosseri confirms that background noise and stumbling are now engagement assets(04:45) Why Gucci is facing major backlash for using AI during Milan Fashion Week(05:55) Jay attempts to have a normal coffee with a friend and realizes he cannot stop interviewing peopleㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Dr Eugene Manley grew up in Detroit in the 1980s cycling through emergency rooms 20 to 30 times a year with asthma and anaphylaxis while hospital staff talked past his family and buried them in paperwork they could not decode. He responded by earning a BS in mechanical engineering an MS in biomedical engineering and a PhD in molecular biology cell biology and biochemistry. Along the way he tore his ACL training for a jiu jitsu black belt worked 86 straight days in a lab during his doctorate and learned how academic and clinical systems punish people who refuse to shrink.In this episode Manley walks through a recent post surgery ordeal at Mount Sinai Queens where staff falsified records attempted an illegal discharge and nearly sent him home on the wrong blood thinner. He explains how medical racism shows up in charts staffing and decision making and why measurable equity fails without accountability. Listeners hear how his STEMM and Cancer Health Equity Foundation builds pipelines for underrepresented students challenges clinical trial design and teaches patients how to protect themselves when institutions lie. RELATED LINKS• Eugene Manley Jr• STEMM and Cancer Health Equity Foundation• Village Voice• LUNGevity FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Michael Skinnider is an Assistant Professor in the Ludwig Princeton Branch of the Ludwig Institute for Cancer Research and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. In this interview, Mike discusses how he got involved in anti-doping research and provides an in-depth look into the novel chemical artificial intelligence (AI) platform he has been developing that is focused on discovering new doping agents. He shares next steps for this line of research and his perspective on the potential impacts of this work for the anti-doping community.

Join Daniel Murray and Jay Schwedelson for a quickfire "Bathroom Break" session packed with immediate marketing takeaways. They break down why specific phrasing in listicles is now essential for ranking in AI search results and share a counterintuitive email subject line hack that is driving open rates up. You will also hear a bizarre personal story about food safety that might make you think twice about your leftovers.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments(01:25) Jay explains why he keeps getting food poisoning from questionable airport and takeout choices(02:22) Daniel recounts the time he had to rescue raw salmon from the garbage for potential lab testing(03:40) Why using "Top 3" or "Number 1" in your headlines is outperforming standard numbered lists(05:00) The smart way to use tools like Perplexity to find high-authority sources for your content(06:25) Testing shows that putting newsletter edition numbers in brackets is actually working right nowㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Brad Marshall and Dr Michael Lisanti join David Gornoski to discuss how anti-ageing research is connected to treating cancer, whether striving for a high metabolic rate is wise, antioxidants vs antibiotics in cancer treatment, reductive stress, effectiveness of B Vitamins, and more.  Follow Brad Marshall on X here. Visit Lunella Biotech's website here. Follow David Gornoski on X here. Visit aneighborschoice.com for more

Stewart Alsop sits down with Ulises Martins on the Crazy Wisdom podcast to explore how artificial intelligence is fundamentally disrupting professional careers, labor markets, and the pace of human adaptation itself. They discuss everything from Dario Amodei's concept of "technological adolescence" to the possibility that we're approaching a point where AI advancement accelerates beyond our ability to keep up, touching on topics ranging from the economics of software development and the future of warfare to generational differences in how people will respond to AI-driven change. Martins emphasizes that while we may not be able to predict exactly what's coming, we need to dramatically increase our efforts to learn and adapt—potentially doubling the time we invest in understanding AI—because this isn't optional change, it's disruption happening at an unprecedented speed. Connect with Ulises on Linkedin to follow his work in AI and generative technology.Timestamps00:00 — Stewart introduces Ulysses Martins, framing the conversation around accelerationism and the future of work.05:00 — Ulises uses the parent-child analogy to argue humans will no longer play the dominant role as AI surpasses us.10:00 — Both agree learning AI is non-negotiable, urging listeners to double their investment in staying current.15:00 — Discussion shifts to software as media, the collapsing cost of building products, and the risk of big players like Anthropic making your idea obsolete overnight.20:00 — Ulises raises ecology vs. cosmic ambition, questioning whether humanity should aim for civilizational-scale goals like the Dyson sphere.25:00 — Stewart's ESP32 hardware project illustrates AI's current blind spots beyond software, while both predict physical-world AI will arrive as a byproduct of bigger industrial goals.30:00 — Tesla's birthplace in Croatia sparks a reflection on human genius as luck versus deliberate investment, invoking the Apollo program as a model.35:00 — The US-China AI race is compared to the Cold War Space Race, with interdependency acting as a brake on outright conflict.40:00 — Drone warfare and AI reframe military power, making troop size irrelevant and potentially reducing total war.45:00 — Agile methodology and generational shifts are linked, asking how Gen Z's values will shape the AI era globally.50:00 — Argentine vs. American Zoomers are contrasted, with millennial expectations versus Gen Z's pragmatism explored.55:00 — Ulises closes urging everyone to enjoy the ride, taking the infinite stream of change one episode at a time.Key Insights1. The Death of Traditional Career Paths: The concept of professional careers as we know them—starting as a junior and progressively advancing—is becoming obsolete due to AI's rapid advancement. This applies far beyond just software and SaaS companies, extending to all industries as robots and AI systems gain capabilities that fundamentally disrupt labor markets. The question isn't whether we'll adapt, but whether humans can adapt fast enough to keep pace with exponential technological change.2. The Acceleration Imperative: People must dramatically increase their investment in learning about AI immediately. Whatever time you were previously dedicating to staying current with technology needs to be doubled or tripled. This isn't optional—it's comparable to the necessity of basic education. Unlike previous technological transitions where you had years to learn new frameworks or tools, the current pace demands immediate, intensive engagement or you risk becoming irrelevant.3. Software as Media and the Collapse of Development Economics: Software has become media—easily reproducible and increasingly commoditized through AI assistance. The fundamental economics of software development are collapsing because if building software requires dramatically fewer development hours, the value and price of that software must necessarily decrease. Entrepreneurs need a new evaluation framework that assesses the risk of their ideas being replicated by AI or absorbed by major players like Anthropic or OpenAI.4. The Parent-Child Analogy for AI Development: Humanity's relationship with AI will inevitably mirror that of parents with increasingly capable children. Initially, we understand and control what AI does, but as it advances, it will surpass human capabilities in most domains. Just as parents cannot control fully grown adult children who exceed their abilities, humans will need to reconcile with creating something superior to ourselves. Attempting to permanently control such systems may be both impossible and potentially pathologic.5. The Kardashev Scale and Civilizational Ambitions: AI represents a civilizational-level technology that should redirect humanity toward grander goals like capturing stellar energy through Dyson spheres and expanding beyond our solar system. The competition between China and the United States over AI mirrors the Apollo program's space race but with higher stakes—potentially making traditional concepts like money less relevant if we successfully crack general intelligence. This requires thinking beyond planetary constraints.6. The Changing Nature of Warfare and Geopolitics: AI and autonomous weapons systems are fundamentally changing warfare by making human soldiers less relevant, similar to how nuclear weapons reduced the importance of conventional military force. This shift may actually reduce bloody civilian casualties in conflicts between major powers, as drone warfare and AI-driven systems create new equilibriums. The geopolitical map may fracture into more sovereign states and city-states as centralized control becomes less effective.7. Generational Adaptation and Unpredictability: Different generations will respond uniquely to AI disruption based on their values and experiences. Generation Z, having grown up during the pandemic without traditional expectations, may adapt differently than millennials who experienced unmet expectations. However, we must remain humble about our predictive abilities—we're not good at forecasting technological change or its timing. The best approach is maintaining openness, trying to understand developments as they unfold, and accepting that we cannot consume all information in an era of unlimited AI-generated content.

AI's starting to make a big difference to cancer research, according to CYRIAC ROEDING during DLD! The post A NEW APPROACH IN CANCER RESEARCH! appeared first on sound*bytes.

Sophia Xu, cofounder of Carbon Bridge, joins us to discuss how her company is revolutionizing gas fermentation with notebook-sized modular bioreactors that convert waste gases into valuable fuels and chemicals. From rejecting medical school to focus on climate biotech, to developing reactors 80% more energy efficient than traditional methods, Sophia shares how Carbon Bridge's platform enables wild-type methanotrophs to perform 500% better than genetically modified microbes. The conversation explores distributed manufacturing, the company's vision for an "app store" of microbial pathways, partnerships with Norwegian Cruise Lines, and why Sophia believes biology—not electrification—is key to decarbonizing heavy industry. We discuss deployment scenarios from dairy farms to breweries, the misconceptions about gas fermentation, and how Carbon Bridge is creating a new business model by selling bioreactors rather than end products.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chapters:(00:00:00) - Sophia's Journey from Cancer Research to Climate Biotech(00:03:18) - AI in Biomanufacturing(00:06:00) - From Nanotechnology to Waste Gas Conversion(00:09:00) - Sophia's Path: Why Climate Over Medical School(00:11:00) - Biology as an Industrial Platform(00:11:48) - Visualizing Carbon Bridge: MacBook-Sized Bioreactors(00:14:00) - Navigating Unpredictability in Biological Systems(00:16:43) - Methanotrophs: The Wild-Type Microbes Behind the Tech(00:17:00) - Scaling by Stacking: From Lab to 80X Scale(00:18:00) - Sustainability Meets Economics: No Green Premium Required(00:21:00) - Performance Numbers: 80% More Efficient, 500% Better Than GMOs(00:23:00) - Distributed Manufacturing and the Server Farm Analogy(00:25:00) - Deployment Scenarios: Dairy Farms, Breweries, and Beyond(00:27:00) - Funding Insights: What ARPA-E, IndieBio, and SOSV Taught Them(00:28:53) - Business Model: Selling Bioreactors, Not End Products(00:30:00) - The App Store Vision for Microbial Pathways(00:32:00) - Carbon Conversion Over Carbon Removal(00:34:00) - Visioneering the Future: Reproducibility and the Biotech Revolution(00:36:00) - Quick Fire: Climate Myths, Hydrogen Skepticism, and More(00:39:00) - Post-Interview Reflections and Business Model SpinLinks and Resources:Links for Sophia's XuTopics Covered:CarbonBridge, climate biotech, gas fermentation, methane to methanol, modular bioreactor, distributed biomanufacturing, waste gas conversion, renewable methanol, industrial biotechnology, biomanufacturing infrastructureHave a question or comment? Message us here:Text or Call (804) 505-5553⁠⁠⁠Instagram⁠⁠⁠ / ⁠⁠⁠Twitter⁠⁠⁠ / ⁠⁠⁠LinkedIn⁠⁠⁠ / ⁠⁠⁠Youtube⁠⁠⁠ / ⁠⁠⁠Grow Everything⁠⁠⁠Music by: Nihilore Production by: Amplafy Media

Send a textWelcome back to The Global Latin Factor Podcast—where we talk Latino everything.Today's guest is Dr. Angelina Ix-Ik' Londoño (PhD, NBC-HWC), founder of Ix-Ik Health & Wellness. Her story is the definition of resilience: she grew up between cultures (“Made in Peru,” born in Honduras, raised in Chicago with Colombian parents), navigated dyslexia, earned her PhD, worked in cancer research, and later made a bold pivot into community wellness—especially for Spanish-speaking communities.In this conversation we get into identity, language, and what it feels like to be “not enough” for either side—plus how she turned that into purpose. We also talk about her journey through genetics and oncology research, the reality of burnout during the pandemic, and what health coaching actually is (and how it's different from internet coaching). Angelina breaks down her 4 pillars—self, community, culture, and nature—and explains why reconnecting with nature, grounding, and community support can be a real reset for your nervous system.If you've been feeling overwhelmed, disconnected, or stuck in the same routine, this episode will hit.

Alex Cattoni is on a mission to humanize the internet, and honestly, we are here for it. She joins Jay Schwedelson to break down why the "bro marketing" era is dying and how empathy is the new currency. They also get into the messy reality of AI in copywriting, exploring why tools like ChatGPT might actually be making real writers more valuable, not obsolete.ㅤCheck out The Copy Posse website or follow Alex on Instagram, LinkedIn, and YouTube.ㅤBest Moments:(01:35) Why the future of marketing combines direct response with empathetic storytelling(03:45) Economics 101 proves that widely available AI content is becoming less valuable(06:15) The danger of treating ChatGPT like a GPS without entering a destination(09:44) Why 55% of companies regret firing their writers for AI tools(11:00) Data shows the demand for human storytelling is actually skyrocketing(15:15) How to spot the difference between good marketing and just pushing buttonsㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Nearly 50% of all cancer deaths are considered preventable, according to the American Association for Cancer Research.However, there remains a general lack of awareness about early detection and screening.This Cancer Prevention Month, doctors are spreading the word about how to be more proactive about your health. We talk to one local researcher to hear more.Guest:Dr. Svasti Haricharan, professor of biology at San Diego State University, member of UC San Diego Moores Cancer Center, research grantee at American Cancer Society

Dr. Campbell explains how animal protein activates cancer pathways, impairs immunity, and promotes carcinogen activity, while plant protein does not. #PlantVsAnimal #CancerScience #ImmuneHealth

If you want to see a massive spike in your LinkedIn engagement, the data says you need to ditch the videos and text-only updates. Jay Schwedelson breaks down why document posts are currently outperforming every other content format by a huge margin. He also shares a simple yet controversial "hack" for Instagram that can double your reach just by rallying five friends in the first hour.ㅤBest Moments:(00:53) Why document posts are seeing 278% more engagement than video right now(02:00) The exact button you need to click to upload a carousel PDF correctly(03:00) How getting five people to DM or share your Instagram story instantly doubles circulation(04:30) Why the President of Burger King is personally answering customer phone calls for four hours a day(05:40) The shocking statistic about how many Americans buy groceries at Walmart every month(06:45) Why a famous actor skipped the Golden Globes to attend a reptile expo in New JerseyㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Jenny Opalinski has spent more than a decade inside hospitals where people lose the ability to speak, breathe, swallow, and sometimes survive. A medical speech language pathologist by training, she worked in ICU, neuro rehab, and long term acute care settings, including a Level 1 trauma center, where she watched clinicians absorb 10 to 15 traumatic events in a single shift and then get told to move the crash cart faster next time.That lived reality pushed her to co found The Wellness Shift, an advocacy and education platform focused on healthcare worker burnout, suicide, and assault. In this conversation, Opalinski walks through the moment that changed everything for her: standing in a hospital hallway listening to a family wail after a failed code, followed by a debrief that addressed logistics and ignored grief entirely.She also explains how that work led to Humanity Rx, her podcast about the human cost of medicine, and Dragon's Breath: Calming Tricks for Big Feelings, a children's book that translates evidence based breathing and regulation strategies into language kids can actually use. The episode covers moral injury, time scarcity, false wellness, respiratory muscle training, and why empathy keeps getting treated as an optional expense instead of clinical infrastructure.RELATED LINKSJenny Opalinski on LinkedInThe Wellness ShiftHumanity RxDragon's Breath: Calming Tricks for Big FeelingsAspire Respiratory ProductsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What does it really take to raise money for a cause that many people misunderstand?  In this conversation, Natalie Reilly-Finch, the Vice President of Growth at the Lung Cancer Research Foundation (LCRF), shares the real challenges behind fundraising for lung cancer research and the responsibility that comes with it. She has been working in fundraising since she was 18 and now leads LCRF's growth efforts. She explains that LCRF is the largest private funder of lung cancer research, helping to close the gap left by limited federal funding. Natalie is deeply committed to changing public perception and supporting everyone affected by lung cancer. During the discussion, Natalie addresses the stigma surrounding lung cancer, especially the belief that it only affects smokers or that it is not a woman's disease. She explains how fundraisers must create urgency without making people feel blamed or judged. She also talks about understanding donor motivations, listening carefully, and using data to build strong connections. Through personal stories and practical advice, Natalie highlights the importance of empathy and flexibility while continuing the fight for a cure. In this episode, you will be able to:  Understand the stigma surrounding lung cancer and how it impacts fundraising efforts. Recognize the importance of balancing urgency with hope in cause-based messaging. Learn how to communicate about sensitive issues without blaming or shaming affected communities. Discover how donor segmentation and data can improve fundraising effectiveness. Gain insights into identifying and aligning with a donor's deeper motivations. Get all the resources from today's episode here.  Support for this show is brought to you by Practivated. Practivated delivers AI-powered donor conversation simulations that let fundraisers practice in a private, judgment‑free space—building confidence, refining messaging, and improving outcomes before the real conversation even begins. Developed by fundraising experts with real‑time coaching at its core, it's the smart way to walk into every donor interaction calm, prepared, and ready to connect. Learn more at practivated.com. Connect with me:  Instagram: https://www.instagram.com/_malloryerickson/ Facebook: https://www.facebook.com/whatthefundraising YouTube: https://www.youtube.com/@malloryerickson7946 LinkedIn: https://www.linkedin.com/mallory-erickson-bressler/ Website: malloryerickson.com/podcast Loved this episode? Leave us a review and rating here: https://podcasts.apple.com/us/podcast/what-the-fundraising/id1575421652 If you haven't already, please visit our new What the Fundraising community forum. Check it out and join the conversation at this link. If you're looking to raise more from the right funders, then you'll want to check out my Power Partners Formula, a step-by-step approach to identifying the optimal partners for your organization. This free masterclass offers a great starting point

Xylitol, FTC Censorship, and the Oral–Heart Health Connection: Nathan Jones, CEO and founder of Xlear, Inc., makers of xylitol-based nasal and dental hygiene products, and a health freedom advocate, discusses Jones' ongoing legal battle with the FTC. He addresses the difficulty of making health claims for hygiene products (including toothpaste and nasal sprays), the role of “weasel words” in supplement marketing, and concerns about regulatory double standards versus pharmaceuticals. He also reviews xylitol's benefits for dental caries and respiratory/ear infections, including references to studies and public-health examples (e.g., Finland and a Belize program reducing dental caries costs), and Jones' efforts to encourage Utah to implement xylitol gum programs in schools. He contrasts fluoride's enamel-strengthening approach with xylitol's effect on the underlying bacterial cause of tooth decay, discusses Utah's fluoride policy change and claims about fluoride's limited benefit, and highlights a correlation between poor oral health and cardiovascular risk via inflammation and bacterial translocation into the bloodstream, including pathogens found in atherosclerotic plaque, and links also discussed for dementia and Parkinson's.  They close with commentary on health advocacy in the “MAHA era,” the challenges of entrenched federal bureaucracy, and Jones' preference for advocacy groups that teach industry to push back rather than comply.

Dr. Hoffman continues his conversation with Nathan Jones, CEO and founder of Xlear, Inc.

Need to boost your open rates while taking a quick break? Jay Schwedelson teams up with Daniel Murray from The Marketing Millennials to break down the latest email subject line tests that are actually working right now. They discuss why screaming in all caps might not be as bad as you think, how to use "accidental" reveals to hook readers, and the psychology behind telling people not to open your emails.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(02:50) Daniel reveals why writing subject lines in ALL CAPS is beating standard text by 4%(03:20) How using a consistent emoji creates a visual anchor for your brand in the inbox(04:30) Jay explains how pattern interruption phrases like "Wait..." stop the scroll(06:15) The "accidental internal reveal" tactic that makes readers feel like insiders(06:45) Using reverse psychology by telling specific audiences to skip your email(09:00) A quick debate on why most TV show reboots are destined to failㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

If I've said it once, I've said it hundreds of times and I won't STOP saying it; put more plants on your plate! Science continues to show the benefit of a plant-forward diet for breast cancer survivors, as well as anyone looking to reduce their risk of heart disease. This month we're exploring foods for both heart and breast health, and in today's episode I show you how strong the overlap is on dietary recommendations from two leading organizations focused on using food for health; the American Heart Association and The American Institute for Cancer Research. And of course, I can't let the month pass without a mention of the recently released Dietary Guidelines! After today's episode you'll understand:Which foods deserve a spot on your Peaceful PlateHow staying up-to-date on nutrition recommendations can prevent nutrition overwhelm and confusionThe common thread between credible nutrition guidelinesClick here to get a copy of 76 Foods for Healthy HeartsFollow me on Instagram @hormone.breastcancer.dietitian

Rochester is now home to one of the nation's 60 NCI-designated cancer centers. Dr. Jonathan Friedberg explains the eight-year journey, the 1,400-page applications, and why this achievement positions our region as a leader in cancer research and treatment. From immunotherapy and precision medicine to cellular therapies and AI, the future of cancer care is being built right here in Western New York.

Love the episode? Send us a text!In this powerful episode of Breast Cancer Conversations, Laura Carfang speaks with Kathy Giusti, a two-time cancer survivor who has lived with multiple myeloma for 30 years and later faced a breast cancer diagnosis as well.Diagnosed at 37 after what she thought was a routine visit, Kathy was told she had a fatal blood cancer and would live “three years at best.” Instead of accepting that prognosis, she helped change the trajectory of cancer research by founding the Multiple Myeloma Research Foundation (MMRF)—a model that brought scientists, clinicians, biotech, and the FDA together to accelerate treatments.This conversation explores survivorship, advocacy, and what patients and caregivers can do when the science is moving fast—but the system isn't.In This Episode, We DiscussGetting a shocking diagnosis after a “routine” appointmentWhy multiple myeloma was once considered a “silent killer”How Kathy helped build a research engine that accelerated drug developmentThe difference between fast-moving science and slow-moving systemsHow Kathy's identical twin impacted her breast cancer risk and screeningDCIS decisions and why “there's no right or wrong—only what's best for you”Why “looking healthy” can cause people to underestimate what you're carryingHow to set boundaries when you're in treatment or survivorshipWhy you shouldn't rely on only one or two caregivers—and how to “invite people in”Kathy's book: Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical SystemResources & LinksFollow Kathy: @kathy.giustiBook: Fatal to Fearless: 12 Steps to Beating Cancer in a Broken Medical SystemSurvivingBreastCancer.org: Free programs, support groups, and communityDownload the SBC App: Search SurvivingBreastCancer.org in the App Store or Google Play Support the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.

Everyone talks about SEO, but are you tracking how your brand shows up in ChatGPT? Jay Schwedelson breaks down why AI Visibility is the new north star metric for marketing teams. He shares a step-by-step guide to auditing your presence on platforms like Gemini and Claude without spending a dime, plus a look at the specific recency signals that help boost your rankings.ㅤBest Moments:(01:45) The number one metric every business needs to add to their toolkit immediately(02:34) How to identify the 10 to 30 priority questions your customers are actually asking AI(03:55) Why you must use an incognito browser when checking your AI search results(05:00) Free tools from SEMrush and Hau that automate the AI visibility tracking process(06:20) The specific recency signal trick to help your content surface in AI answers(07:30) A very honest review of Love Is Blind Season 10 and the movie RIPㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Soap operas are back, but they look a lot different on TikTok, and even B2B brands need to pay attention to this exploding trend. Jay Schwedelson explains why serialized micro-dramas are the new engagement goldmine and how to adapt the format for professional content. He also shares fresh research on why adding just a few extra links to your email marketing campaigns might be destroying your click-through rates.Best Moments:(00:55) TikTok launches "Pine" to capitalize on the exploding micro-drama trend(01:52) Why Deloitte predicts this bite-sized content format will generate billions this year(02:20) How B2B marketers can use serialized storytelling on LinkedIn to boost engagement(03:22) New data shows hero offer clicks drop by 50% when an email has three or more links(04:50) Mondelez leans into internet culture with their hilarious "Nepo Cookie" campaign(05:50) The problem with "nepo babies" demanding privacy while oversharing on social mediaCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Marketing attribution often feels like a guessing game where everyone just ends up giving credit to Google Search. Jay Schwedelson connects with Daniel Murray from The Marketing Millennials to break down why you should treat attribution data as a directional compass rather than a precise GPS. They discuss practical ways to validate your data, including the power of holdout groups and geo-testing, plus a random side conversation about whether Olympic curlers are actually the best athletes in the world.Follow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.Best Moments:(01:50) Why attribution should be viewed as a compass instead of a turn-by-turn GPS(02:22) The problem with giving Google Search all the credit for last-touch conversions(03:10) How to set up a holdout group to measure the true lift of your campaigns(04:09) Using geo-based testing to see if specific channels are actually driving growth(04:45) Why it is a red flag if one channel claims 100% of the credit in a multi-touch world(05:15) The surprisingly effective "How did you hear about us?" form field strategy(06:40) A hot take on whether curling athletes are actually the best in the worldCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Today's episode is one we truly, deeply hoped we'd never have to record. But… here we are. James Van Der Beek passed away on Wednesday, February 11, 2026, after a two‑year battle with colon cancer. And listen… even after spending nearly a decade watching Dawson's Creek, we still weren't prepared for the gut punch of this news. Yes — we really have been doing this podcast that long, and no, we don't want to talk about it. As the hosts of Basic Teen TV, we never expected this actor — someone who first entered our lives through a '90s teen drama — to become such a constant presence that he essentially set up camp in our lives. So we wanted to record a short episode to honor him. Something small, something honest. A way to process what his loss means — not just for us, but for the generation that grew up watching him navigate heartbreaks far bigger than the creek he stood beside. James wasn't just a familiar face from TV; he shaped a generation's emotional vocabulary. He was a cultural touchstone for millennials — a man whose single tear could launch a thousand memes and still somehow make us feel something real. His passing hit us harder than expected. But here's the thing: while James may be gone, what he gave us isn't. The warmth, the vulnerability, the sincerity he brought to every role — it stays. His legacy, especially his unforgettable portrayal of Dawson Leery, will stay with us forever. Because if there's anything James taught us, it's that you can cry dramatically and still keep going. Support for James Van Der Beek's Family Colorectal Cancer Alliance American Cancer Society Susan G. Komen The V Foundation for Cancer Research  

If you have ever thought about quitting your agency job to start your own consultancy, Jessica Best has the blueprint on how to actually make it work. She joins Jay Schwedelson to break down why betting on yourself is less scary than staying in a job that drives you crazy. They also get into a heated debate over email marketing hot takes, including why resending to non-openers might be a waste of time and why most A/B tests fail to prove anything useful.ㅤConnect with Jessica on LinkedIn or visit her website at Jessica.BestㅤBest Moments:(02:00) Why getting mad at your current situation is the best fuel for starting a business(04:23) The terrifying reality of keeping your sales pipeline full when you work for yourself(06:30) Jessica argues that resending emails to non-openers is actually a bad strategy(08:00) Jay reveals his aggressive subject line trick for getting people to open the second time(10:00) Why testing every single email you send is a terrible idea that drives you crazy(14:00) The myth of the perfect day and time to send an email campaignㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

A cancer diagnosis can be devastating. And the chemotherapy that often follows can be particularly rigorous. The American Cancer Society projects that 2.1 million people in the United States will be diagnosed with cancer in 2026—but researchers are making major advances in cancer treatment and patient survival. Ziyang Zhang is a chemist and 2023 Pew-Stewart Scholar for Cancer Research who leads cutting-edge studies on reducing the negative effects of chemotherapy on cancer patients. In his lab at the University of California, Berkeley, he and his team are producing new tools at the chemical level that will help to develop more effective therapies to target cancer mutations and avoid damage to healthy cells.

We are seeing a massive shift in urgency with big brands launching campaigns months earlier than usual. Jay Schwedelson explains why "preseason marketing" is surging and shares a clever "first 100" registration tactic that leverages FOMO to drive immediate action. You also get the lowdown on a new Reddit ad unit that drives leads for cheap and a heated debate about which pizza chain actually tastes like pizza.ㅤBest Moments:(00:36) Why preseason marketing is becoming the dominant trend for 2026(01:40) How major brands like Salesforce are selling events a year in advance(02:52) The specific "first 100" phrasing that increases webinar signups by 20%(04:09) Using the concept of control to get people to register early(05:15) Reddit's new Reminder Ads that let you test traffic for cheap(05:56) Pizza Hut closing 250 stores and the debate over chain pizza quality(07:58) Why the new reality show about neighbor feuds is peak televisionㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most marketing podcasts don't start with a debate about the structural integrity of nachos, but this isn't most podcasts. Jay Schwedelson and Daniel Murray team up for a "Bathroom Break" session that pivots from Super Bowl snacks to the specific AI tools actually worth using right now. They skip the doom-and-gloom headlines to share exactly what software is saving them hours on writing, slide decks, and video editing.ㅤFollow Daniel on LinkedIn and check out The Marketing Millennials podcast for sharp, no-fluff marketing insights. Subscribe to Ari Murray's newsletter at gotomillions.co for sharp, actionable marketing insights.ㅤBest Moments:(01:39) Daniel shares his specific layering technique for making the perfect plate of nachos(02:25) Why the Anthropic Super Bowl commercial perfectly captured the current nerd rivalry(03:30) Claude is beating ChatGPT and Gemini for creative writing tasks(04:05) The tool Jay uses to generate full slide presentations in seconds(05:12) Descript remains the top choice for editing video and audio through text(06:00) How to build a functional app in 15 minutes without writing a single line of code(11:13) A healthier hack for the classic onion soup dip recipeㅤCheck out Jay's YOUTUBE Channel: https://www.youtube.com/@schwedelsonCheck out Jay's TIKTOK: https://www.tiktok.com/@schwedelsonCheck Out Jay's INSTAGRAM: https://www.instagram.com/jayschwedelson/ㅤPre-order Jay Schwedelson's new book, Stupider People Have Done It (out April 21, 2026). All net proceeds are donated to The V Foundation for Cancer Research—let's kick cancer's butt: https://www.amazon.com/Stupider-People-Have-Done-Marketing/dp/1637635206